Date: 2013-06-25
Type of information: Licensing agreement
Compound: PASylated blood clotting factor - application of PASylation® technology to a cytokine
Company: XL-protein (Germany) Generium (Russia)
Therapeutic area:
Type agreement: collaboration
licensing
Action mechanism: XL-protein\'s proprietary PASylation® technology is a biological alternative to PEGylation, conferring an expanded hydrodynamic volume onto the biopharmaceutical which leads to retarded kidney filtration based on a molecular size effect. A tunable prolonged plasma half-life by a factor 10-100 has been demonstrated for various compounds in preclinical animal studies.
Disease:
Details: * On June 25, 2013, XL-protein and GENERIUM have announced the closing of a license and a collaboration agreement. Under these agreements, XL-protein will license a PASylated blood clotting factor and apply its proprietary PASylation® technology for plasma-half life extension to a cytokine, respectively, for use in the Russian Federation and Commonwealth of Independent States (CIS). GENERIUM acquires exclusive marketing rights for the Russian Federation and CIS and will assume responsibility for further development and marketing of said compounds within this territory. XL-protein retains development and marketing rights for Rest of World.
First data from this collaboration will be presented at the 38th Congress of the Federation of European Biochemical Societies (FEBS) in St. Petersburg, Russia, July 6-11, 2013.
GENERIUM is a Russian innovative biotechnology company with a strong focus on drug discovery and development, production and marketing of biotechnology products. GENERIUM includes a modern international biotechnology center and a renovated manufacturing production unit covering a complete spectrum of technologies.
Financial terms: Under the terms of the license agreement, XL-protein receives a seven digit US$ upfront payment upon signing of the agreement. In addition, XL-protein will receive payments for the achievement of preclinical, clinical, regulatory, and commercial milestones as well as significant royalties on sales.
Latest news:
